Dr Reddys Stock Analysis

RDY
 Stock
  

USD 54.56  0.10  0.18%   

The current indifference towards the small price fluctuations of Dr Reddys Laboratories created some momentum for investors as it was traded today as low as 54.41 and as high as 54.94 per share. The company directors and management did not add any value to Dr Reddys Laboratories investors in October. However, most investors can still diversify their portfolios with Dr Reddys Laboratories to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.48. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Additionally, take a look at Your Equity Center.
  
The Dr Reddys stock analysis report makes it easy to digest most publicly released information about Dr Reddys and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Dr Reddys Stock analysis module also helps to analyze the Dr Reddys price relationship with some important fundamental indicators such as market cap and management efficiency.

Dr Reddys Stock Analysis Notes

The company has price-to-book ratio of 0.05. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Dr Reddys Laboratories has Price/Earnings To Growth (PEG) ratio of 0.7. The entity last dividend was issued on the 8th of July 2021. The firm had 2:1 split on the 7th of September 2006. Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people. To find out more about Dr Reddys Laboratories contact MARC KIKUCHI at 91 40 4900 2900 or learn more at https://www.drreddys.com.

Dr Reddys Laboratories Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Dr Reddys' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Dr Reddys Laboratories or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Dr Reddys has high likelihood to experience some financial distress in the next 2 years
Latest headline from news.google.com: Dr. Reddys Laboratories To Face Antitrust Litigation, Along With Other Generic Pharma Companies In US, - Inventiva

Dr Reddys Laboratories Upcoming and Recent Events

Earnings reports are used by Dr Reddys to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dr Reddys previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of February 2017
Next Financial Report11th of May 2017
Next Fiscal Quarter End31st of December 2016
Next Fiscal Year End11th of May 2017
Last Quarter Report30th of September 2016
Last Financial Announcement31st of December 2015

Dr Reddys Largest EPS Surprises

Earnings surprises can significantly impact Dr Reddys' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2005-07-26
2005-06-300.060.05-0.0116 
2019-05-17
2019-03-310.330.37250.042512 
2020-07-29
2020-06-300.520.46-0.0611 
View All Earnings Estimates

Dr Reddys Thematic Classifications

In addition to having Dr Reddys stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Obamacare
Companies that count on Obamacare to take off

Dr Reddys Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Dr Reddys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dr Reddys Laboratories backward and forwards among themselves. Dr Reddys' institutional investor refers to the entity that pools money to purchase Dr Reddys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares5.1 K332 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares5.1 K374 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares5.1 K312 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares5.1 K363 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares11.6 K806 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares22 K1.2 M
Zurcher Kantonalbank Zurich CantonalbankCommon Shares22 K887 K
Note, although Dr Reddys' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Dr Reddys Market Capitalization

The company currently falls under 'Mid-Cap' category with total capitalization of 9.07 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dr Reddys's market, we take the total number of its shares issued and multiply it by Dr Reddys's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Dr Reddys Profitablity

Dr Reddys' profitability indicators refer to fundamental financial ratios that showcase Dr Reddys' ability to generate income relative to its revenue or operating costs. If, let's say, Dr Reddys is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Dr Reddys' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Dr Reddys' profitability requires more research than a typical breakdown of Dr Reddys' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 13.68 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 16.51 %, which entails that for every 100 dollars of revenue, it generated 0.17 of operating income.

Management Efficiency

The entity has Return on Asset of 7.81 % which means that on every $100 spent on asset, it made $7.81 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.71 %, implying that it generated $15.71 on every 100 dollars invested. Dr Reddys management efficiency ratios could be used to measure how well dr reddys laboratories manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 28th of November, Dr Reddys owns the Market Risk Adjusted Performance of 0.0764, downside deviation of 1.61, and Standard Deviation of 1.48. In respect to fundamental indicators, the technical analysis model provides you with a way to check possible technical drivers of Dr Reddys Laboratories, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Dr Reddys, which can be compared to its peers in the sector. Please confirm Dr Reddys Laboratories standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Dr Reddys Laboratories is priced favorably, providing market reflects its prevailing price of 54.56 per share. Given that Dr Reddys Laboratories has jensen alpha of 0.025, we urge you to verify Dr Reddys's latest market performance to make sure the company can sustain itself in the future.

Dr Reddys Laboratories Price Movement Analysis

The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Exponential Moving Average is calculated by weighting recent values of Dr Reddys Laboratories more heavily than older values.
.

Dr Reddys Technical and Predictive Indicators

Dr Reddys Forecast Models

Dr Reddys time-series forecasting models is one of many Dr Reddys' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dr Reddys' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Dr Reddys Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Dr Reddys prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dr Reddys shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Dr Reddys. By using and applying Dr Reddys Stock analysis, traders can create a robust methodology for identifying Dr Reddys entry and exit points for their positions.
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people.

Current Dr Reddys Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dr Reddys analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dr Reddys analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
48.95Hold2Odds
Dr Reddys Laboratories current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Dr Reddys analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dr Reddys stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dr Reddys Laboratories, talking to its executives and customers, or listening to Dr Reddys conference calls.
Dr Reddys Analyst Advice Details

Dr Reddys Stock Analysis Indicators

Dr Reddys Laboratories stock analysis indicators help investors evaluate how Dr Reddys stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dr Reddys shares will generate the highest return on investment. By understating and applying Dr Reddys stock analysis, traders can identify Dr Reddys position entry and exit signals to maximize returns.
Quick Ratio1.23
Trailing Annual Dividend Rate25.00
Fifty Two Week Low47.88
Revenue Growth6.00%
Payout Ratio13.98%
Shares Short Prior Month1.69M
Average Daily Volume Last 10 Day234.03k
Average Daily Volume In Three Month237.63k
Earnings Growth107.90%
Shares Percent Shares Out0.94%
Earnings Quarterly Growth108.10%
Gross Margins52.52%
Forward Price Earnings18.22
Float Shares117.01M
Fifty Two Week High65.86
Enterprise Value To Ebitda-0.02
Fifty Day Average53.46
Two Hundred Day Average53.85
Enterprise Value To Revenue-0.00
Trailing Annual Dividend Yield45.89%
Additionally, take a look at Your Equity Center. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Dr Reddys Stock analysis

When running Dr Reddys Laboratories price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know Dr Reddys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.12
Market Capitalization
B
Quarterly Revenue Growth YOY
0.094
Return On Assets
0.0903
Return On Equity
0.16
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of Dr Reddys that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine Dr Reddys value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.